Summary
A fixed-ratio combination of insulin degludec and liraglutide significantly improves glycemic control in patients with type 2 diabetes mellitus (T2DM) compared with either drug as monotherapy, with a low risk of hypoglycemia. This article discusses data from a Phase 3 randomized, 3-arm, open-label study.
- Diabetes Mellitus
- Hyperglycemia/Hypoglycemia
- Diabetes & Endocrinology Clinical Trials
- Diabetes Mellitus
- Endocrinology
- Diabetes & Metabolic Syndrome
- Hyperglycemia/Hypoglycemia
- Diabetes & Endocrinology Clinical Trials
- © 2013 MD Conference Express®
Tools
Fixed-Ratio Combination of Insulin Degludec and Liraglutide Improves Glycemic Control in Type 2 Diabetes
Permalink:
Table of contents
Cited By...
- No citing articles found.